First Deal Of Scangos Era Brings Phase II ALS Candidate To Biogen Idec
This article was originally published in The Pink Sheet Daily
Big biotech pays $80 million to Knopp Biosciences for worldwide license to dexpramiprexole.
You may also be interested in...
Between 2010 and the first quarter of 2013, biopharma engaged in 70 deals involving neurodegenerative disease assets covering a wide variety of targets – possibly a consequence of uncertainty about the underlying pathophysiology. AstraZeneca was the top deal maker in the field even as it moved away from CNS as a core therapeutic area.
New understanding of the spectrum of CNS disorders and rising interest from biotechs have revealed new targets, new biomarkers and new opportunities to treat the fast-acting and deadly neurodegenerative disease. Add to that an open stakeholder forum hosted by FDA Feb. 25 that could clarify regulatory and clinical expectations, and the tide may be turning on amyotrophic lateral sclerosis.
Biogen CEO George Scangos spoke about the unnecessary overlap of the company's corporate venture fund and its business development unit at Windhover's recent Pharmaceutical Strategic Alliance conference.